FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2180813806> ?p ?o ?g. }

• W2180813806 endingPage "721" @default.
• W2180813806 startingPage "710" @default.
• W2180813806 abstract "This clinical trial (DT7995) was designed to evaluate amsacrine (AMSA) plus cytosine arabinoside (ara-C), vincristine, and prednisone (OAP) therapy in previously untreated patients with adult acute leukemia and to investigate a new strategy for assignment of patients to treatment using estimated probabilities of complete remission (PPR) based on six prognostic factors. In the first stage of the trial, patients with unfavorable prognosis (PPR less than .40) received AMSA-OAP for remission induction and patients with favorable prognosis (PPR greater than or equal to .40) received Adriamycin [Adria Laboratories, Columbus, OH] plus OAP (Ad-OAP). As AMSA-OAP was found to be promising in patients with unfavorable prognosis, it was administered to relatively more favorable patients (PPR less than .60) in the second stage of the trial and to all patients in the third stage. There were 242 patients entered into study; 134 received AMSA-OAP and 108 received Ad-OAP. Outcomes were compared with 242 paired patients who received Ad-OAP therapy from 1973 to 1977. The estimated complete remission rate in previously untreated adults with acute leukemia is 61% for patients receiving Ad-OAP (95% confidence interval, 59% to 64%). Overall, the survival experience for the 242 patients on DT7995 was significantly better than that in the control series (P = .03), but there was no strong statistical evidence (P = .10) that the 134 patients receiving AMSA-OAP had better survival than control patients receiving Ad-OAP, with a median of 32 v 21 weeks, respectively. It is concluded that AMSA-OAP is equivalent to Ad-OAP in the induction of complete remissions (estimated complete remission rate, 61%) and that assignment of patients to treatment based on predicted prognosis is an ethical and efficient strategy for the evaluation of new therapies in previously untreated patients with acute leukemia." @default.
• W2180813806 created "2016-06-24" @default.
• W2180813806 creator A5027575595 @default.
• W2180813806 creator A5031020853 @default.
• W2180813806 creator A5038302480 @default.
• W2180813806 creator A5049208967 @default.
• W2180813806 creator A5057920623 @default.
• W2180813806 creator A5066206647 @default.
• W2180813806 creator A5073798523 @default.
• W2180813806 creator A5090435894 @default.
• W2180813806 date "1987-05-01" @default.
• W2180813806 modified "2023-10-18" @default.
• W2180813806 title "A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia." @default.
• W2180813806 cites W1529957398 @default.
• W2180813806 cites W1757201400 @default.
• W2180813806 cites W1934064433 @default.
• W2180813806 cites W1996923775 @default.
• W2180813806 cites W2007027766 @default.
• W2180813806 cites W2025060073 @default.
• W2180813806 cites W2029378155 @default.
• W2180813806 cites W203809443 @default.
• W2180813806 cites W2054368189 @default.
• W2180813806 cites W2064608254 @default.
• W2180813806 cites W207118996 @default.
• W2180813806 cites W2083948119 @default.
• W2180813806 cites W2143594378 @default.
• W2180813806 cites W2218795077 @default.
• W2180813806 cites W2262859612 @default.
• W2180813806 cites W2286738661 @default.
• W2180813806 cites W2333326790 @default.
• W2180813806 cites W2406249232 @default.
• W2180813806 cites W2409221803 @default.
• W2180813806 cites W2604629598 @default.
• W2180813806 cites W35584703 @default.
• W2180813806 doi "https://doi.org/10.1200/jco.1987.5.5.710" @default.
• W2180813806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3553435" @default.
• W2180813806 hasPublicationYear "1987" @default.
• W2180813806 type Work @default.
• W2180813806 sameAs 2180813806 @default.
• W2180813806 citedByCount "41" @default.
• W2180813806 countsByYear W21808138062012 @default.
• W2180813806 countsByYear W21808138062016 @default.
• W2180813806 countsByYear W21808138062017 @default.
• W2180813806 countsByYear W21808138062022 @default.
• W2180813806 crossrefType "journal-article" @default.
• W2180813806 hasAuthorship W2180813806A5027575595 @default.
• W2180813806 hasAuthorship W2180813806A5031020853 @default.
• W2180813806 hasAuthorship W2180813806A5038302480 @default.
• W2180813806 hasAuthorship W2180813806A5049208967 @default.
• W2180813806 hasAuthorship W2180813806A5057920623 @default.
• W2180813806 hasAuthorship W2180813806A5066206647 @default.
• W2180813806 hasAuthorship W2180813806A5073798523 @default.
• W2180813806 hasAuthorship W2180813806A5090435894 @default.
• W2180813806 hasConcept C126322002 @default.
• W2180813806 hasConcept C146357865 @default.
• W2180813806 hasConcept C151730666 @default.
• W2180813806 hasConcept C2776694085 @default.
• W2180813806 hasConcept C2776755627 @default.
• W2180813806 hasConcept C2776863199 @default.
• W2180813806 hasConcept C2778119113 @default.
• W2180813806 hasConcept C2778461978 @default.
• W2180813806 hasConcept C2778720950 @default.
• W2180813806 hasConcept C2779429289 @default.
• W2180813806 hasConcept C2780500152 @default.
• W2180813806 hasConcept C3018657049 @default.
• W2180813806 hasConcept C44249647 @default.
• W2180813806 hasConcept C535046627 @default.
• W2180813806 hasConcept C71924100 @default.
• W2180813806 hasConcept C86803240 @default.
• W2180813806 hasConcept C90924648 @default.
• W2180813806 hasConceptScore W2180813806C126322002 @default.
• W2180813806 hasConceptScore W2180813806C146357865 @default.
• W2180813806 hasConceptScore W2180813806C151730666 @default.
• W2180813806 hasConceptScore W2180813806C2776694085 @default.
• W2180813806 hasConceptScore W2180813806C2776755627 @default.
• W2180813806 hasConceptScore W2180813806C2776863199 @default.
• W2180813806 hasConceptScore W2180813806C2778119113 @default.
• W2180813806 hasConceptScore W2180813806C2778461978 @default.
• W2180813806 hasConceptScore W2180813806C2778720950 @default.
• W2180813806 hasConceptScore W2180813806C2779429289 @default.
• W2180813806 hasConceptScore W2180813806C2780500152 @default.
• W2180813806 hasConceptScore W2180813806C3018657049 @default.
• W2180813806 hasConceptScore W2180813806C44249647 @default.
• W2180813806 hasConceptScore W2180813806C535046627 @default.
• W2180813806 hasConceptScore W2180813806C71924100 @default.
• W2180813806 hasConceptScore W2180813806C86803240 @default.
• W2180813806 hasConceptScore W2180813806C90924648 @default.
• W2180813806 hasIssue "5" @default.
• W2180813806 hasLocation W21808138061 @default.
• W2180813806 hasLocation W21808138062 @default.
• W2180813806 hasOpenAccess W2180813806 @default.
• W2180813806 hasPrimaryLocation W21808138061 @default.
• W2180813806 hasRelatedWork W1921119956 @default.
• W2180813806 hasRelatedWork W1969288783 @default.
• W2180813806 hasRelatedWork W2014270506 @default.
• W2180813806 hasRelatedWork W2034483742 @default.
• W2180813806 hasRelatedWork W2064930805 @default.
• W2180813806 hasRelatedWork W2076235097 @default.

• next